Perrigo Licenses Antihistamine Levocetirizine, “Prime” Switch Candidate
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's licensing agreement with Synthon Pharmaceuticals to market a generic of UCB's antihistamine Xyzal brings the private labeler a "prime example" of an Rx-to-OTC switch candidate. Switch is a "likely scenario" for the allergy drug, Perrigo maintains
You may also be interested in...
Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches
Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period
Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches
Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period
Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches
Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period